This survey report explores how hub models for patient support strategies are evolving and stabilizing, and which ones are gaining momentum.
Two-year comparative insights from 200 biopharmaceutical leaders reveal that external pressures persist and shifts in patient support strategies continue to rely on outsourcing. But manufacturers have signaled they now bring sharper expectations and stronger motivations for insourcing select functions. These models are gaining momentum as demand rises for hybrid models and more flexible vendor relationships.
This report explores comparisons between 2024 and 2026 survey results to highlight where hub models are stabilizing, where they are shifting and what manufacturers expect next. This flexibility is shaping a more modern, adaptable era of patient services. Findings include:
- How manufacturers are testing new hub models against their internal strengths and opportunities, and where hybrid models are fitting in.
- The evolving motivators, confidence levels, and competitive edge for insourcing.
- What they are doing to better align hub structures with longer-term strategic goals.
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and Cardinal Health
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and Cardinal Health
